Roivant Sciences (NASDAQ:ROIV) Director Sells $610,245.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 17,750 shares of Roivant Sciences stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the transaction, the director owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This represents a 51.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $35.13 on Friday. The company has a market capitalization of $25.27 billion, a P/E ratio of -58.55 and a beta of 1.11. The business’s 50 day moving average is $30.24 and its two-hundred day moving average is $27.26. Roivant Sciences Ltd. has a 12-month low of $10.70 and a 12-month high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period last year, the company earned ($0.29) earnings per share. On average, research analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Citigroup increased their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. TD Cowen lifted their target price on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Sanford C. Bernstein started coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 target price for the company. Finally, Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and an average target price of $33.59.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. lifted its holdings in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after buying an additional 520 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Roivant Sciences during the fourth quarter worth $47,000. Finally, Bessemer Group Inc. raised its position in shares of Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after buying an additional 441 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.